Almac and Beactica sing drug discovery agreement
Under the agreement, Beactica will use its drug discovery platform, Sprint, to identify high-quality fragment hits against a number of undisclosed targets of therapeutic interest to Almac Discovery.
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.